JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk - Reply

Circ J. 2022 Jun 24;86(7):1205. doi: 10.1253/circj.CJ-22-0285. Epub 2022 May 27.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / drug therapy
  • Factor Xa Inhibitors / adverse effects
  • Hemorrhage / chemically induced
  • Humans
  • Retrospective Studies
  • Rivaroxaban / adverse effects
  • Stroke* / etiology
  • Stroke* / prevention & control
  • Treatment Outcome

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Rivaroxaban